

STUDY OF INTERACTION BETWEEN TIGECYCLINE AND SULBACTAM

ABSTRACT

Drug interactions can have desired, reduced or unwanted effects. The probability of interactions increases with the number of drugs taken. Side effects or therapeutic drug interactions can increase or decrease the effects of one or two drugs. "Failure may result from clinically meaningful interactions." Clinicians rarely use foreseeable drug-drug interactions to produce the desired therapeutic effect. For example, when we consider two drugs each causing, peripheral neuropathy increases the likelihood of neuropathy occurrence. The selection of alternative treatment options with antibiotic combinations may be used to successfully manage multidrug-resistant *Acinetobacter baumannii*. Liu et al., studied combined therapy of tigecycline with cefoperazone-sulbactam and reported that it was seemingly superior treatment option compared to monotherapy or the combination of tigecycline with sulbactam alone. In this study geometry optimizations of tigecycline and sulbactam drugs and their combination have been carried out with the evaluation of B3LYP/6-311G (d,p), B3LYP/6-311G (2d,2p) levels, and the reaction mechanism at semi empirical PM6, which was parameterized for biochemical systems and B3LYP/6-311G (d,p) levels. The main objective of the study is to understand the interaction of sulbactam with tigecycline, to describe energetic condition of bond formation and electronic structure (orders of the broken and formed bonds). The reaction mechanisms of sulbactam with tigecycline have been studied as stepwise and concerted mechanisms using semi-empirical PM6 and B3LYP/6-311G (d,p) levels

12
13
14
15
16
17
18
19

Keywords: Tigecycline and Sulbactam, Semi-empirical, PM6, B3LYP

1. INTRODUCTION

Sulbactam, is the β -lactamase inhibitors in clinical use. Sulbactam sodium (SBT) named as 4-thia-1-azabicyclo [3.2.0] heptane 2-carboxylic acid, 3,3-dimethyl-7-oxo-4,4 dioxo sodium salt, and it is official in the British Pharmacopoeia [1].

20 Tigecycline representing a new class of antimicrobials known as glycylycylines is (4S,4aS,-
21 5aR,12aS)-9-(2-tert-butylaminoacetyl-amino)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-
22 1,11-dioxo-1,4,4a,5,5a,-6,11,12a-octahydronaphthacene-2-carboxamide [2] and it has more
23 potent activity against a variety of tetracycline-resistant and multidrug-resistant Gram-positive
24 and Gram-negative bacterial pathogens. Because of its microbiological, pharmacodynamic and
25 pharmacokinetic properties, this antibiotic has been evaluated as monotherapy for serious
26 infections in human clinical trials [3,4].

27 The effects of meropenem, imipenem, sulbactam, colistin, and tigecycline, alone or in
28 combination, on biofilm-embedded were investigated due to difficulty in destruction of

29 Acinetobacter baumannii biofilms [5] and reported that Significant decreases in the maximum
30 biofilm thickness were observed after exposure to meropenem and imipenem. Meropenem plus
31 sulbactam significantly decreased the biomass and mean thickness and increased the
32 roughness coefficient of biofilms, but sulbactam plus tigecycline only decreased the maximum
33 and mean biofilm thickness compared to any of these agents used alone.

34 The clinical efficacy between salvage antimicrobial regimen consisting of tigecycline plus
35 extended-infusion imipenem/cilastatin (TIC) and regimen of sulbactam plus imipenem/cilastatin
36 (SIC) for patients with ventilator-associated pneumonia and pneumonic bacteremia due to
37 extensively drug-resistant (XDR) Acinetobacter baumannii (Ab) isolates were compared and
38 determined the correlation of results of in vitro tigecycline + imipenem synergy test with clinical
39 efficacy [6].

40 Numerous studies have shown that combinations of tigecycline and sulbactam are promising
41 treatment options for MDR A. baumannii. They tested ten clinical isolates of A. baumannii
42 sensitive colistin and tigecycline synergistic effects of tigecycline and sulbactam and reported
43 that Tigecycline MIC values decreased 2-4 fold with sulbactam and this combination resulted in
44 synergy or partial synergy in 50% of the isolates [7].

45 In vitro study conducted on 25 XDR A. baumannii, it has been shown that sulbactam plus
46 tigecycline provides synergy or additional effects at 84% of stains and no antagonism [8]

47 In this work, we present a density functional theoretical and semi-empirical studies on the
48 mechanism of the reaction between the sulbactam, and tigecycline. The calculated reaction
49 mechanism is presented and discussed in a general way.

50

51 **2. MATERIAL AND METHODS**

52

53 **2.1. COMPUTATIONAL DETAILS**

54 All the reactants, products and transition states have been optimized again within the semi-
55 empirical method-pm6 and density functional theory (DFT) framework, by using the B3LYP
56 functional. This functional is based on Becke's three-parametrization adiabatic connection
57 method (ACM) and consists of a combination of Slater [9] Hartree-Fock, [10] and Becke[11]
58 exchange functionals, the Vosko, Wilk, and Nusair (VWN) local correlation functional,[12] and
59 the Lee, Yang, and Parr [13] nonlocal correlation functional. The IRC have been computed
60 automatically using intrinsic reaction coordinate (IRC), following algorithms. IRC was proposed
61 by Fukui in 1970 as a pathway of chemical reactions, 1, 2, the steepest descent path weighted
62 predominantly on the potential energy surface (PES), starting from the transition (TS), ie the
63 first rank saddle point. Starting from nonstationary structures, the mass - weighted steepest
64 descent path is called meta - IRC. The calculations have been carried out with the GAUSSIAN
65 09 series of programs [14].


66

67 **3. RESULTS AND DISCUSSION**

68

69 The relative energies of the ground and transition states in the addition of tigecycline to
70 sulbactam in gas media are presented in Figure 1 that the reactant located on the left side in
71 the diagram reaches the product on the right side via several intermediates and transition
72 states. These profiles were obtained from the results of analysis of the PES by relaxed
73 scanning over the reaction coordinate using the B3LYP/6311G(d,p) method.


74 Two transition states for stepwise mechanism are depicted as saddle points, and the energies
 75 required to go over each barrier ($\Delta G1$, $\Delta G2$) are called activation energies. One transition
 76 state for concerted mechanism is depicted as saddle point and activation energy is $\Delta G3$.
 77



78
 79
 80
 81
 82
 83
 84
 85

Fig. 1. Reaction energy diagram

The concerted and stepwise mechanisms for the bond formation are illustrated with the
 optimized structures of the reactants, the three transition states and one intermediate, and for
 products calculated with B3LYP/6-311G(d,p) level in Fig 2.



86
 87
 88
 89
 90
 91

Fig. 2 Reaction mechanism between sulbactam and tigecycline

In this reaction we considered the reaction between the HOMO of tigecycline and the LUMO of
 sulbactam. For both the B3LYP and PM6 success was achieved when the interaction of
 tigecycline N lone pair with the carbonyl centre of sulbactam was performed. When considering
 both the charge interaction and most likely the HOMO/LUMO interactions led to the conclusion

92 that glycine react with sulbactam by nucleophilic attack of tigecycline nitrogen (N) lone pair on
93 the carbonyl carbon C7 of sulbactam considered the reaction between the HOMO of tigecycline
94 and the LUMO of sulbactam. HOMO, LUMO, electron density of the optimized structures of
95 reactants, IN, transition states and products are shown in Figure 3.

96 Electrostatic potential maps enable us to visualize the charge distributions of molecules and
97 charge related properties of molecules. They also allow us to visualize the size and shape of
98 molecules. Different colors represent the different values of the electrostatic potential at the
99 surface. Potential increases in the ordered (most negative) < orange < yellow < green < blue
100 (most positive). (MEP) surfaces are plotted over the optimized electronic structure of reactants,
101 the three transition states and one intermediate, and for products calculated with B3LYP/6-
102 311G(d,p) level in Fig 3. MEP surface directly provides information about the electrophilic
103 (electronegative charge region) and nucleophilic (most positive charge region) regions.

104 In general, two molecules which are either the two atoms that have highest and opposite
105 charges or two atoms that have a highest electron densities in their highest occupied or lowest
106 unoccupied atomic molecular orbital's interact each other.


107 In the first step nitrogen lone pair of one amino group belonging to tigecycline attacks the
108 carbonyl carbon atom of the sulbactam, molecule leading to the formation of C-N bond which is
109 the addition step. The second step is the elimination of water molecule.

110 For the stepwise process, an intermediate INT1 is separated from reactants by 19.21 kcal/mol
111 barrier at transition state TS1 and from products by 34.64 kcal/mol at transition state TS2. For
112 concerted process 3 is separated from reactants by 58.43 kcal/mol at transition state TS3.
113 Vibration analysis was performed for the reactants, intermediates, transition states and final
114 molecules. We found a negative imaginary frequency which is characteristic of an ordinary TS
115 for transitional states (TS). Generally, an imaginary frequency for TS is the first order saddle.
116 The imaginary frequencies for TS1 and TS2 in the stepwise **proces process** are -338 cm⁻¹
117 and -1655 cm⁻¹, and for concerted mechanism TS3 is -970 cm⁻¹.

118 The reacting molecules tigecycline and sulbactam (1+2). being far from each other (N1- C7 =
119 3.000 Å) have a summary energy -1973192 kcal/mol with the calculation B3LYP/6-311G(d,p)
120 level for both **tigecycline tigecycline** and sulbactam.

121 From Table 1 it was found that the bonds between N-H is 1.01 Å and 1.03 Å for B3LYP and
122 PM3 respectively and bond length for O=C is 1.20 Å and 1.21 Å, respectively while sulbactam
123 and **ttigliisin tigecycline** were sufficiently far apart, the bonds between N-H in the course of
124 reaction increase by 1.32 Å and 0.11 Å for B3LYP and PM3 respectively. While for O=C it
125 increases by 0.03 Å and 0.19Å for B3LYP and PM3 respectively. All these are due to pulling of
126 electron by the reacting atoms in the transition state (TS1). The N1-C7 bond between
127 tigecycline and sulbactam is partially formed at the TS1. N1-C7 bond length with the calculation
128 B3LYP in the course of reaction changes to 2.15 Å, 1.49 Å, 1.50 Å and 1.39 Å at TS1, IN, TS2
129 and 3, respectively.

130
131



132

133

134

135

136

137

138

139

Fig. 3 ESP, HOMO, LUMO of reactants, intermediate, transition states and products

The distance between the ~~the~~-carbon and nitrogen involved in the formation of the new N–C single bonds in the synchronous TS1 and in IN is found to be 2.15 Å and 1.49 Å for B3LY/6-311G(d,p) and 3.32 Å and 1.50 Å for PM6 level. The distance between the ~~the~~-carbon and nitrogen involved in the formation of the new N–C single bonds in TS3 is found to be 2.13 Å and 1.49 Å for B3LY/6-311G(d,p) and PM6 levels.

140 Now let's consider TS2. The C7-O9 distance of 1.65 Å and 1.62 Å for B3LYP/6-311G(d,p) and
 141 PM7 levels, respectively compared to the approximation value of 1.350 Å for a single bond,
 142 does not suggest any significant bonding between those two atoms.

143 The Mulliken charges of atom C7 at 1+2, TS3 and 3 for calculations with B3LYP/6-311G(d,p) are
 144 0.38 e⁻, 0.038 e⁻, 0.41 e⁻, respectively; charges on atom N1 at 1+2, TS3 and 3 are -0.50 e⁻, -
 145 0.65 e⁻, -0.38 e⁻, and those of atoms O8 and O9 are -0.33 e⁻, -0.31 e⁻ for 1+2, -0.23 e⁻, -0.543
 146 e⁻ for TS3 and -0.38 e⁻, -0.50 e⁻ for 3. Different orbitals overlapping cause changing of Mulliken
 147 charges.

148
 149
 150
 151

Table 1. Bond Lengths and Mulliken charges of the reactants, the three transition states and one intermediate, and products

Atom Numbers	B3LYP/6-311g(d,p)						PM6					
	1+1	TS1	IN	TS2	TS3	3	1+1	TS1	IN	TS2	TS3	3
Bond Lengths (Å)												
N ₁ -C ₄	1.40	1.29	1.39	1.37	1.38	1.41	1.41	1.35	1.42	1.41	1.44	1.42
C ₄ -C ₆	1.50	1.47	1.49	1.49	1.50	1.49	1.48	1.44	1.47	1.48	1.47	1.47
C ₄ -O ₅	1.21	1.32	1.23	1.24	1.21	1.21	1.22	1.31	1.23	1.23	1.24	1.22
N ₁ -H ₂	1.01	2.33	2.33	2.32	1.04	3.73	1.03	1.14	2.54	2.55	1.81	3.43
N ₁ -H ₃	1.01	1.02	1.01	1.02	1.01	1.01	1.01	1.00	1.03	1.03	1.05	1.04
N ₁ -C ₇	3.00	2.15	1.49	1.50	2.13	1.39	3.50	3.32	1.50	1.50	1.56	1.42
C ₇ -O ₈	1.20	1.23	1.38	1.25	1.18	1.22	1.21	1.21	1.40	1.25	1.42	1.22
C ₇ -O ₉	1.35	1.35	1.39	1.65	1.70	2.80	1.37	1.37	1.41	1.64	1.38	2.80
O ₉ -H ₁	0.97	0.97	0.97	1.80	2.40	1.82	1.00	1.00	0.99	1.89	0.99	4.07
O ₈ -H ₂	2.06	1.64	0.98	1.04	1.55	0.96	2.00	1.99	1.02	1.03	1.07	0.97
O ₈ -H ₁₁	2.31	2.28	2.27	0.98	0.97	0.97	2.37	2.37	2.25	1.04	2.32	1.01
C ₇ -C ₁₁	1.53	1.53	1.56	1.55	1.56	1.53	1.53	1.53	1.58	1.57	1.56	1.54
C ₁₁ -N ₁₂	1.47	1.47	1.46	1.48	1.46	1.46	1.48	1.47	1.47	1.47	1.48	1.47
C ₁₁ -C ₁₃	1.56	1.57	1.57	1.55	1.56	1.57	1.55	1.55	1.55	1.55	1.56	1.56
Mulliken charges(e ⁻)												
O ₅	-0.32	-0.32	-0.39	-0.40	-0.37	-0.34	-0.57	-0.71	-0.57	-0.57	-0.56	-0.57
N ₁	-0.50	-0.55	-0.45	-0.50	-0.65	-0.38	-0.61	-0.54	-0.64	-0.64	-0.62	-0.56
C ₆	-0.13	-0.07	-0.13	-0.15	-0.13	-0.14	-0.63	-0.64	-0.62	-0.62	-0.69	-0.70
C ₄	0.32	0.36	0.43	0.42	0.40	0.40	0.69	0.64	0.73	0.73	0.73	0.77
H ₂	0.24	0.22	0.24	0.27	0.23	0.24	0.27	0.30	0.29	0.29	0.31	0.31
H ₃	0.23	0.28	0.27	0.31	0.33	0.28	0.29	0.37	0.39	0.37	0.45	0.34
O ₉	-0.31	-0.32	-0.37	-0.38	-0.45	-0.50	-0.53	-0.53	-0.56	-0.57	-0.72	-0.66
O ₈	-0.33	-0.45	-0.39	-0.46	-0.23	-0.38	-0.52	-0.50	-0.60	-0.68	-0.60	-0.52
N ₁₂	-0.33	-0.33	-0.37	-0.33	-0.35	-0.34	-0.46	-0.45	-0.46	-0.46	-0.45	-0.39
C ₁₃	-0.51	-0.51	-0.45	-0.48	-0.48	-0.49	-0.28	-0.29	-0.27	-0.26	-0.27	-0.28
C ₁₁	0.38	0.06	0.04	-0.03	0.07	0.05	-0.05	-0.04	-0.06	-0.05	-0.04	-0.08
C ₇	0.38	0.46	0.39	0.46	0.38	0.41	0.63	0.63	0.67	0.67	0.67	0.62
H ₁₁	0.27	0.25	0.25	0.28	0.28	0.28	0.34	0.34	0.35	0.44	0.34	0.38

152
 153
 154
 155
 156
 157
 158

Substantial characters of materials are obtained with the quantum chemical calculations. Computational calculation is an alternate choice due to difficulty to measure hyperpolarizability directly, The first order-hyperpolarizability and related properties of sulbactam and tigecycline and sulbactam- tigecycline were calculated using B3LYP/6-311G(d,p) basis set, based on the finite field approach. The mean first-order hyperpolarizability can be calculated using the equation 1.

159
$$\beta_{total} = \sqrt{(\beta_{xxx} + \beta_{xyy} + \beta_{xzz})^2 + (\beta_{yyx} + \beta_{yzz} + \beta_{yxx})^2 + (\beta_{zzx} + \beta_{zxx} + \beta_{zyy})^2}$$
 (1)

160 According to Koopman's theorem [15] chemical hardness, electronegativity and chemical
161 potential can be defined as:

162
$$\eta = 1/2 (E_{LUMO} - E_{HOMO})$$
 (2)

163
$$\mu = -\chi = 1/2 (E_{HOMO} + E_{LUMO})$$
 (3)

164 Global softness which is one of the most important reactivity descriptors is defined as the
165 inverse of global hardness as in the given following equation: [16,17]

166
$$\sigma = 1/\eta$$
 (4)

167 Electrophilicity (ω) is another parameter and indicates tendency of the molecule to accept
168 electrons. Electrophilicity index explain the electrophilic and nucleophilic behavior of molecules.
169 Electrophilicity index is defined via equation 5 [18]. A good electrophile means high
170 electronegativity (or chemical potential) and low chemical hardness values.

171
$$\omega = \mu^2/2\eta$$
 (5)

172 Nucleofugality (ΔE_n), Electrofuqality (ΔE_e) are useful theoretical descriptors and may be
173 calculated with equation 6 and 7.

174
$$\Delta E_n = -A + \omega = (\mu + \eta)^2/2\eta$$
 (6)

175
$$\Delta E_e = I + \omega = (\mu - \eta)^2/2\eta$$
 (7)

176 The results in Table 2 establish the influence of tigecycline, sulbactam and tigecycline-
177 sulbactam on the first hyperpolarizability and the other descriptors calculated with B3LYP(6-
178 311G(d,p) and B3LYP(6-311G(2d,2p) levels. The ω values are the largest for the tigecycline-
179 sulbactam than for the alone tigecycline and alone sulbactam. The established order is as
180 follows: sulbactam > tigecycline > tigecycline-sulbactam

181 The lowest unoccupied molecular orbital - E_{LUMO} , The highest occupied molecular orbital
182 energies- E_{HOMO} , hardness, softness, electronegativity, energy gap, chemical potential,
183 electrophilicity index, nucleofugality, electrofuqality are given in Table 2.

184 Eventual charge transfer interaction is taking place within the molecule is explained with the

185 The HOMO and LUMO energy gap. Hardness defined the gap between the HOMO and LUMO
186 orbital energies is associated with the stability of the chemical. The gap energies between
187 E_{HOMO} and E_{LUMO} for tigecycline, sulbactam and tigecycline sulbactam calculated with the
188 B3LYP/6-311G(d,p) level are 3.286 eV, 6.579 eV, and 3.379 eV, respectively and 3.347 eV,
189 6.599 eV and 3.397 eV with the B3LYP/6-311G(2d,2p) level.

190

191 **Table 2. Some descriptors for tigecycline, sulbactam and tigecycline sulbactam**

192

193

	tigecycline	sulbactam	tigecycline-sulbactam
--	-------------	-----------	-----------------------

	6-311 G(d,p)	6-311 G(2d,2p)	6-311 G(d,p)	6-311 G(2d,2p)	6-311 G(d,p)	6-311 G(2d,2p)
E_{LUMO}	-2.376	-2.342	-0.903	-0.829	-2.481	-2.433
E_{HOMO}	-5.661	-5.689	-7.482	-7.428	-5.859	-5.831
ΔE	3.286	3.347	6.579	6.599	3.379	3.397
η	1.643	1.673	3.290	3.299	1.689	1.699
S	0.304	0.299	0.152	0.152	0.296	0.294
χ	4.018	4.016	4.192	4.128	4.170	4.132
μ	-4.018	-4.016	-4.192	-4.128	-4.170	-4.132
ω	4.915	4.818	2.671	2.583	5.147	5.025
ΔE_{in}	1.717	1.639	0.124	0.104	1.822	1.743
ΔE	4.093	3.982	1.026	0.933	4.303	4.176
$\beta(10^{-30} \text{ esu})$	10.954	10.873	1.398	2.082	20.427	20.120

194
195
196
197
198
199
200

4. CONCLUSION

The reaction is nucleophilic in nature in which the nitrogen lone pair of tigecycline attacks the carbonyl carbon (C7) of sulbactam to form tigecycline- sulbactam adduct. The two methods are in good agreement with one another since they produced two transition states and one intermediate for stepwise mechanism and one transition for concerted mechanism.

201 The HOMO–LUMO calculations show that the energy gap increases with the combination of
202 tigecycline- sulbactam.

203
204
205

REFERENCES

1. B. Pharmacopoeia. British Pharmacopoeia Commission London; the Department of Health. Social Services and Public Safety. 2013;1:719-20.
2. Hoffmann M, DeMaio W, Jordan RA, Talaat R, Harper D, Speth J et al. Metabolism, Excretion, and Pharmacokinetics of [¹⁴C]Tigecycline, a First-In-Class Glycylcycline Antibiotic, after Intravenous Infusion to Healthy Male Subjects. *Drug Metabolism and Disposition*. 2007;35(9):1543-53.
3. Chopra I. Glycylcyclines: third-generation tetracycline antibiotics. *Curr Opin Pharmacol*. 2001;1(5):464-9.
4. Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, et al. The glycylcyclines: a comparative review with the tetracyclines. *Drugs*. 2004;64(1):63-88.
5. Wang YC, Kuo SC, Yang YS, Lee YT, Chiu CH, Chuang MF, et al. Individual or Combined Effects of Meropenem, Imipenem, Sulbactam, Colistin, and Tigecycline on Biofilm-Embedded *Acinetobacter baumannii* and Biofilm Architecture. *Antimicrob Agents Chemother*. 2016;60(8):4670-6.
6. Jean SS, Hsieh TC, Hsu CW, Lee WS, Bai KJ, Lam C. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant *Acinetobacter baumannii* bacteremia, and correlation of clinical efficacy with in vitro synergy tests. *J Microbiol Immunol Infect*. 2016;49(6):924-33.

- 225 7. Cai Y, Bai N, Liu X, Liang B, Wang J, Wang R. Tigecycline: Alone or in combination?.
226 Infectious Diseases. 2016;48(7):491-502.
- 227 8. Falagas ME, Vardakas KZ, Tsiveriotis KP, Triarides NA, Tansarli GS. Effectiveness and
228 safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial
229 infections. *Int J Antimicrob Agents*. 2014;44(1):1-7.
- 230 9. Slater JC. *Quantum Theory of Molecular and Solids*. McGrawHill. New York, 1974; Vol. 4.f
- 231 10. Fock VZ. *Physic* 1930;61:126.
- 232 11. Becke AD. Density-functional exchange-energy approximation with correct asymptotic
233 behavior. *Phys Rev. A* 1988;38:3098.
- 234 12. Vosko SH, Wilk L, Nusair M. Accurate spin-dependent electron liquid correlation energies
235 for local spin density calculations: a critical analysis. *Canadian Journal of Physics*,
236 1980;58(8):1200-11.
- 237 13. Lee C, Yang W, Parr. Development of the Colle-Salvetti correlation-energy formula into a
238 functional of the electron density. *Phys. Rev. B* 1988;37:785.
- 239 14. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman, J. R, et al.
240 Gaussian Inc. Wallingford CT. 2009.
- 241 15. Koopmans T. Über die Zuordnung von Wellenfunktionen und Eigenwerten zu den Einzelnen
242 Elektronen Eines Atoms. *Physica*. 1934;1(1-6):104-13. German.
- 243 16. Yang W, Lee C, Ghosh SK, Molecular softness as the average of atomic softnesses:
244 companion principle to the geometric mean principle for electronegativity equalization, *J. Phys*
245 *Chem*. 1985;89(25):5412-14.
- 246 17. YangW, Parr RG. Hardness, softness, and the fukui function in the electronic theory of
247 metals and catalysis. *Proc Natl Acad Sci*. 1985;82(20):6723-6.
- 248 18. Parr RG, Sventpaly L, Liu S. Electrophilicity Index. *J Am Chem Soc* 1999;121(9):1922-4.